Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985393 | 1.00 | HTR1B (0.67) | HTR1BGPR35MCHR1PDE1BACHE | |
| SCHEMBL6391176 | 1.00 | HTR1B (0.67) | HTR1BGPR35MCHR1PDE1BACHE | |
| SCHEMBL5994036 | 0.81 | HTR1B (1.00) | HTR1BMCHR1 | |
| SCHEMBL14263969 | 0.81 | HTR1B (1.00) | HTR1BMCHR1 | |
| SCHEMBL4988681 | 0.80 | HTR1B (0.63) | HTR1BGPR35PDE1BKDM4EHPGD | |
| SCHEMBL4990154 | 0.77 | HTR1B (0.43) | HTR1BGPR35MCHR1PDE1BACHE | |
| SCHEMBL4989817 | 0.76 | HTR1B (0.65) | HTR1BGPR35KDM4EHPGD | |
| SCHEMBL4985861 | 0.72 | HTR1B (0.68) | HTR1BGPR35PDE1BACHEMAOA | |
| SCHEMBL4990158 | 0.70 | GPR35 (0.56) | GPR35PDE1BKDM4EHPGDKMT2A | |
| SCHEMBL4987195 | 0.67 | HTR1B (0.59) | HTR1BGPR35PDE1BKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| US-20060019947-A1 | Therapeutic chromone compounds | CHAPDELAINE MARC | 2006-01-26 | — | — | US | disclosed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | ASTRAZENECA AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | PIERSON EDWARD (US) | 2005-01-13 | — | — | US | disclosed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| US-20040110745-A1 | Therapeutic chroman compounds | INTEL CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-20040087575-A1 | Therapeutic chromone compounds | SPORT COURT INTERNATIONAL, INC. | 2004-05-06 | — | — | US | disclosed |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | HTR1B 2/4885GPR35 113/4885MCHR1 73/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | HTR1B 1/4885GPR35 326/4885MCHR1 79/4885 |
| US-20040087575-A1 | Therapeutic chromone compounds | HTR1B, HTR1A, HTR3B | HTR1B 1/4885GPR35 634/4885MCHR1 41/4885 |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | HTR1B, HTR1A, HTR1D | HTR1B 1/4885GPR35 298/4885MCHR1 80/4885 |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | HTR1B 1/4885GPR35 214/4885MCHR1 52/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | HTR1B 1/4885GPR35 214/4885MCHR1 52/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | HTR1B 3/4885GPR35 251/4885MCHR1 36/4885 |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | HTR1B 3/4885GPR35 204/4885MCHR1 45/4885 |
| US-20060019947-A1 | Therapeutic chromone compounds | HTR1B, HTR3B, HTR1A | HTR1B 1/4885GPR35 696/4885MCHR1 51/4885 |
| US-20040110745-A1 | Therapeutic chroman compounds | HTR1A, ACHE, CALCA | HTR1B 29/4885GPR35 444/4885MCHR1 72/4885 |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | HTR1D, HTR1B, HTR1A | HTR1B 2/4885GPR35 160/4885MCHR1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.